fashion -WSS

fashion

author：knowledge 2025-09-27 22:46:13 - browse：668

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Key House panel plots a new health care package

WSS

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Readout Newsletter: The latest on Novavax, Merck, Bluebird

At Orexo, a ‘turning point’ for everything but digital health

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Merck CEO won’t testify in Senate, citing no expertise in drug prices

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

Why Medicare shouldn’t cover every FDA

Jerome Adams on the need for new antivirals for Covid

Key House panel plots a new health care package

The cancer drug shortage isn’t new — and neither are the solutions

At Orexo, a ‘turning point’ for everything but digital health

Hepatitis C has a cure — but many Americans still lack access to it

Why Medicare shouldn’t cover every FDA

Alkermes shareholders re

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

hotspot

Bernie Sanders is gearing up to subpoena pharma CEOs

As digital health tech proliferates, a new institute aims to cut through hype

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Humana’s losses in Medicare Advantage tank its stock

Merck, Johnson & Johnson CEOs will testify on high drug prices

FTC sues over Novant Health acquisition of two N.C. hospitals

leisure time

entertainment

entertainment

Wikipedia